Literature DB >> 17006874

Specific symptomatic changes following donepezil treatment of Alzheimer's disease: a multi-centre, primary care, open-label study.

Kenneth Rockwood1, Sandra Black, Marc-Andre Bedard, Thang Tran, Isabelle Lussier.   

Abstract

BACKGROUND: Standard measurement scales used in anti-dementia trials may not capture symptomatic changes recognized by clinicians and caregivers. We studied a symptom checklist, completed separately by caregivers and by clinicians, to identify patterns of change associated with donepezil treatment.
METHODS: In a multi-centre, 6-month, open-label study of 101 primary care patients, changes in a 19-symptom checklist were assessed in relation to changes in standardized scales of cognition, activities of daily living, behavior, and caregiver burden.
RESULTS: Three symptoms were reported in more than 80% of patients by both clinicians and caregivers: problems in remembering, (97%), temporal orientation (89%), and repetitiveness (85%). Five others overlapped on each of the clinician and caregiver 'top ten', including cognitive activation, spatial orientation, leisure, attention, and apathy. Clinicians reported that symptoms did not improve in 38 patients, whereas there was some improvement in 43, and improvement in most symptoms in 20. Caregivers reported that symptoms did not improve in 55 patients, whereas 27 and 19 patients showed some and most symptoms improving respectively. Patients with the greatest symptomatic improvement also improved most on the ADAS-Cog and the other standardized measures, whereas no improvement (or decline) in each standardized measure was observed in people whose symptoms worsened or did not improve.
CONCLUSION: A symptom checklist allowed clinically meaningful profiles to be identified, but revealed different estimates of response between clinicians and caregivers. Both agreed that improved executive function was the most common response. A symptom checklist can help translate between standard measures and everyday practice.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17006874     DOI: 10.1002/gps.1675

Source DB:  PubMed          Journal:  Int J Geriatr Psychiatry        ISSN: 0885-6230            Impact factor:   3.485


  6 in total

1.  Validation of an informant-reported web-based data collection to assess dementia symptoms.

Authors:  Kenneth Rockwood; An Zeng; Chris Leibman; Lisa Mucha; Arnold Mitnitski
Journal:  J Med Internet Res       Date:  2012-03-12       Impact factor: 5.428

Review 2.  Donepezil for dementia due to Alzheimer's disease.

Authors:  Jacqueline S Birks; Richard J Harvey
Journal:  Cochrane Database Syst Rev       Date:  2018-06-18

Review 3.  Apathy in Alzheimer's disease: any effective treatment?

Authors:  Raffaele Rea; Anna Carotenuto; Angiola M Fasanaro; Enea Traini; Francesco Amenta
Journal:  ScientificWorldJournal       Date:  2014-02-02

4.  Unmet Needs in Pharmacological Treatment of Apathy in Alzheimer's Disease: A Systematic Review.

Authors:  Christos G Theleritis; Kostas T Siarkos; Antonios M Politis
Journal:  Front Pharmacol       Date:  2019-10-04       Impact factor: 5.810

5.  Safety and efficacy of donepezil hydrochloride in patients with mild to moderate Alzheimer's disease: Findings of an observational study.

Authors:  Suyog Mehta; K Chandersekhar; G Prasadrao; Lakshman Dutt; S Patkar; R D Nagpal; M Gupta; G S P Raju; K K Praveen; B S V Prasad; T Roy; S Kushwaha; Jyotindra Nag; D Langade; D Pawar
Journal:  Indian J Psychiatry       Date:  2012-10       Impact factor: 1.759

6.  Donepezil may reduce the risk of comorbidities in patients with Alzheimer's disease: A large-scale matched case-control analysis in Japan.

Authors:  Hiroyuki Kobayashi; Heii Arai
Journal:  Alzheimers Dement (N Y)       Date:  2018-04-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.